The Biomanufacturing Excellence Act of 2025 proposes to establish a National Biopharmaceutical Center of Excellence under the National Institute of Standards and Technology (NIST). This Center will be created through a competitive grant or agreement awarded by the NIST Director to an eligible non-federal entity, such as a public-private partnership or institution of higher education. Its primary goal is to bolster the United States' capabilities in biopharmaceutical manufacturing, reducing reliance on foreign supply chains and accelerating the development of critical medicines. The Center of Excellence will focus on several key objectives, including advancing the science of biopharmaceutical manufacturing , particularly for products vital to national, health, and economic security. This involves developing flexible manufacturing technologies, improving upstream and downstream processes, and enhancing equipment to reduce supply bottlenecks. Furthermore, it will support good manufacturing practices , quality by design, and standardization to ensure efficient production and regulatory clarity for innovative methods. A crucial aspect of the Center's mission is to advance workforce training and development , collaborating with educational and community partners to cultivate biotechnology talent. It will also foster the deployment of innovative biopharmaceutical manufacturing infrastructure by engaging a broad range of stakeholders, including universities, pharmaceutical manufacturers, government agencies, and non-profit organizations. The bill authorizes $120,000,000 for fiscal year 2026 to support the Center's establishment, facility construction, collaborative research, and workforce programs.